These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

711 related items for PubMed ID: 30012439

  • 1. In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.
    Seifert H, Blondeau J, Dowzicky MJ.
    Int J Antimicrob Agents; 2018 Oct; 52(4):474-484. PubMed ID: 30012439
    [Abstract] [Full Text] [Related]

  • 2. Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.
    Zhang Z, Chen M, Yu Y, Pan S, Liu Y.
    Antimicrob Resist Infect Control; 2018 Oct; 7():152. PubMed ID: 30564308
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R, Noriega ER, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2015 Dec 15; 14():53. PubMed ID: 26667651
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
    Decousser JW, Woerther PL, Soussy CJ, Fines-Guyon M, Dowzicky MJ.
    Antimicrob Resist Infect Control; 2018 Dec 15; 7():68. PubMed ID: 29876099
    [Abstract] [Full Text] [Related]

  • 8. Activity of tigecycline and comparators against skin and skin structure pathogens: global results of the Tigecycline evaluation and surveillance trial, 2004-2009.
    Namdari H, Tan TY, Dowzicky MJ.
    Int J Infect Dis; 2012 Jan 15; 16(1):e60-6. PubMed ID: 22104303
    [Abstract] [Full Text] [Related]

  • 9. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
    Liu JW, Ko WC, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Chen YH, Lu PL, Sun W, Wang LS, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR.
    Antimicrob Agents Chemother; 2012 Mar 15; 56(3):1414-7. PubMed ID: 22155819
    [Abstract] [Full Text] [Related]

  • 10. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
    Dowzicky MJ, Park CH.
    Clin Ther; 2008 Nov 15; 30(11):2040-50. PubMed ID: 19108792
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.
    Marco F, Dowzicky MJ.
    J Glob Antimicrob Resist; 2016 Sep 15; 6():50-56. PubMed ID: 27530839
    [Abstract] [Full Text] [Related]

  • 13. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang JL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR.
    Antimicrob Agents Chemother; 2012 Mar 15; 56(3):1452-7. PubMed ID: 22203598
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
    Fernández-Canigia L, Dowzicky MJ.
    Ann Clin Microbiol Antimicrob; 2012 Oct 22; 11():29. PubMed ID: 23088592
    [Abstract] [Full Text] [Related]

  • 16. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS, Whitelaw A, Dowzicky MJ.
    Int J Antimicrob Agents; 2014 Feb 22; 43(2):170-8. PubMed ID: 24315313
    [Abstract] [Full Text] [Related]

  • 17. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS, Jones RN, Dowzicky MJ, Fritsche TR.
    Diagn Microbiol Infect Dis; 2005 Jul 22; 52(3):203-8. PubMed ID: 16105565
    [Abstract] [Full Text] [Related]

  • 18. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec 22; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.